A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.
about
Endless Resistance. Endless Antibiotics?Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.Breakthroughs in the treatment and prevention of Clostridium difficile infection.Screening of Bifidobacteria and Lactobacilli Able to Antagonize the Cytotoxic Effect of Clostridium difficile upon Intestinal Epithelial HT29 Monolayer.Therapies on the horizon for Clostridium difficile infections.Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates.Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.New antibiotics in clinical trials for Clostridium difficile.Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.Novel Antimicrobials for the Treatment of Clostridium difficile Infection.
P2860
Q28822179-105D5A43-AF91-4E4C-B0D9-A92C76F9B94DQ33831557-DD69F85D-D22E-4237-B042-7CC4C644A93BQ35918566-148BDDD5-3A4F-45F8-ACB3-5602B7A15B6AQ36823908-2C573779-E1EA-4E88-B5C4-15F9533FE27EQ38757930-93554ADE-7BE2-4305-AF76-54C01BE0C33EQ39723636-59D65228-1C78-4FFD-89D8-C0C54682C3F4Q40130108-4B494D50-3DAD-447B-968B-FF6E9CE3592DQ40615409-4FE0D03F-40B0-4DA6-A29D-DA0CBEA28254Q40916483-B9D29C34-85BA-414C-88A7-809CA940DA4AQ54245367-B1111819-A808-4436-B738-BAD3C5064D64Q55405974-47FF126D-91EB-4115-953D-6621FAE61B2A
P2860
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A randomised phase 1 study to ...... stridium difficile infections.
@ast
A randomised phase 1 study to ...... stridium difficile infections.
@en
type
label
A randomised phase 1 study to ...... stridium difficile infections.
@ast
A randomised phase 1 study to ...... stridium difficile infections.
@en
prefLabel
A randomised phase 1 study to ...... stridium difficile infections.
@ast
A randomised phase 1 study to ...... stridium difficile infections.
@en
P2093
P2860
P1476
A randomised phase 1 study to ...... ostridium difficile infections
@en
P2093
Glenn Tillotson
Mark Wilcox
Roger Echols
P2860
P2888
P356
10.1186/S12879-015-0759-5
P577
2015-02-25T00:00:00Z
P5875
P6179
1006887364